Anacalypsis Therapeutics is a biotechnology company that develops medications and biomarkers for neurodegenerative diseases.
Anacalypsis Therapeutics has raised $344K in total funding. The most recent round was Pre-Seed. The last funding was announced in September 2026.
Anacalypsis Therapeutics's investors include Metavallon VC.
Anacalypsis Therapeutics is headquartered in Pikérmi, Greece.
Anacalypsis Therapeutics is a biotechnology company that develops medications and biomarkers for neurodegenerative diseases.
Anacalypsis Therapeutics is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Anacalypsis Therapeutics — Funding & Investors." VCBacked, September 21, 2026, https://www.vcbacked.co/company/anacalypsis-therapeutics. Accessed October 1, 2026.
VCBacked. (2026). Anacalypsis Therapeutics — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/anacalypsis-therapeutics
{{cite web |title=Anacalypsis Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/anacalypsis-therapeutics |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated